Juerg Schwaller

List of Publications by Year
in descending order

80 papers	5,491 citations	126907 33 h-index	106344 65 g-index
84 all docs	84 docs citations	84 times ranked	8132 citing authors

#	Article	IF	Citations
1	Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood, 2008, 111, 3931-3940.	1.4	402
2	Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. Nature, 2014, 512, 78-81.	27.8	375
3	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20523-20528.	7.1	342
4	PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica, 2010, 95, 1004-1015.	3.5	307
5	Stat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2. Molecular Cell, 2000, 6, 693-704.	9.7	289
6	Programmed death 1 signaling on chronic myeloid leukemiaâ€“specific T cells results in T-cell exhaustion and disease progression. Blood, 2009, 114, 1528-1536.	1.4	250
7	Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO Journal, 1998, 17, 5321-5333.	7.8	249
8	Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature, 2019, 572, 254-259.	27.8	246
9	PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains. Cancer Research, 2013, 73, 3336-3346.	0.9	218
10	Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. Cancer Research, 2015, 75, 5106-5119.	0.9	193
11	Structural Analysis Identifies Imidazo[1,2-b]Pyridazines as PIM Kinase Inhibitors with In vitro Antileukemic Activity. Cancer Research, 2007, 67, 6916-6924.	0.9	183
12	MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. Cancer Cell, 2016, 30, 43-58.	16.8	176
13	Socs-1 Inhibits TEL-JAK2-Mediated Transformation of Hematopoietic Cells through Inhibition of JAK2 Kinase Activity and Induction of Proteasome-Mediated Degradation. Molecular and Cellular Biology, 2001, 21, 3547-3557.	2.3	157
14	Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood, 2007, 109, 331-338.	1.4	138
15	Dissection of PIM serine/threonine kinases in FLT3-ITDâ€“induced leukemogenesis reveals PIM1 as regulator of CXCL12â€“CXCR4-mediated homing and migration. Journal of Experimental Medicine, 2009, 206, 1957-1970.	8.5	128
16	Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy. Cell Metabolism, 2020, 32, 829-843.e9.	16.2	122
17	H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor Î² gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood, 2001, 97, 3910-3918.	1.4	120
18	TEL/PDGFÎ²R Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor. Blood, 1999, 93, 1707-1714.	1.4	111

#	Article	IF	Citations
19	Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells.. Journal of Clinical Investigation, 1995, 95, 973-979.	8.2	111
20	The expression of ETV6/CBFA2 (TEL/AML1) is not sufficient for the transformation of hematopoietic cell lines in vitro or the induction of hematologic disease in vivo. Cancer Genetics and Cytogenetics, 2001, 130, 93-104.	1.0	107
21	High-Throughput Kinase Profiling: A More Efficient Approach toward the Discovery of New Kinase Inhibitors. Chemistry and Biology, 2011, 18, 868-879.	6.0	105
22	Targeting PIM Kinases Impairs Survival of Hematopoietic Cells Transformed by Kinase Inhibitorâ€“Sensitive and Kinase Inhibitorâ€“Resistant Forms of Fms-Like Tyrosine Kinase 3 and BCR/ABL. Cancer Research, 2006, 66, 3828-3835.	0.9	97
23	Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. Science Advances, 2016, 2, e1600760.	10.3	90
24	Downregulation of 14-3-3Ïƒ in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Modern Pathology, 2005, 18, 340-348.	5.5	83
25	Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Modern Pathology, 2009, 22, 476-487.	5.5	79
26	MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-ÎºB-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood, 2005, 105, 2891-2899.	1.4	77
27	Genetic alterations in urothelial bladder carcinoma. Cancer, 2006, 106, 1205-1216.	4.1	72
28	Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia. Blood, 2008, 111, 5672-5682.	1.4	70
29	PIM Kinases Are Essential for Chronic Lymphocytic Leukemia Cell Survival (PIM2/3) and CXCR4-Mediated Microenvironmental Interactions (PIM1). Molecular Cancer Therapeutics, 2014, 13, 1231-1245.	4.1	61
30	Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction. Haematologica, 2014, 99, 1465-1471.	3.5	44
31	Validation and Structural Characterization of the LEDGF/p75â€“MLL Interface as a New Target for the Treatment of MLL-Dependent Leukemia. Cancer Research, 2014, 74, 5139-5151.	0.9	41
32	Murine Models of Acute Myeloid Leukaemia. International Journal of Molecular Sciences, 2019, 20, 453.	4.1	40
33	Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. Leukemia, 2019, 33, 1360-1372.	7.2	40
34	Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogeneâ€“Driven Myeloid Leukemia. Cancer Discovery, 2019, 9, 1736-1753.	9.4	37
35	LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. Blood, 2018, 131, blood-2017-05-786962.	1.4	32
36	Expression of Leukemia-Associated Nup98 Fusion Proteins Generates an Aberrant Nuclear Envelope Phenotype. PLoS ONE, 2016, 11, e0152321.	2.5	29

#	Article	IF	Citations
37	Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. Blood, 2020, 136, 698-714.	1.4	28
38	Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention. Frontiers in Pediatrics, 2019, 7, 401.	1.9	27
39	Prostate-Specific Membrane Antigen Expression Is a Potential Prognostic Marker in Endometrial Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 571-577.	2.5	21
40	TEL/PDGFÎ²R Induces Hematologic Malignancies in Mice That Respond to a Specific Tyrosine Kinase Inhibitor. Blood, 1999, 93, 1707-1714.	1.4	21
41	Nuclear interacting SET domain protein 1 inactivation impairs GATA1-regulated erythroid differentiation and causes erythroleukemia. Nature Communications, 2020, 11, 2807.	12.8	18
42	Loss of CCDC6 Affects Cell Cycle through Impaired Intra-S-Phase Checkpoint Control. PLoS ONE, 2012, 7, e31007.	2.5	16
43	A Novel Inducible Mouse Model of MLLâ€ENLâ€driven Mixedâ€lineage Acute Leukemia. HemaSphere, 2018, 2, e51.	2.7	14
44	Dual roles of EZH2 in acute myeloid leukemia. Journal of Experimental Medicine, 2019, 216, 725-727.	8.5	14
45	Aggressive leukemia driven by MLL-AF9. Molecular and Cellular Oncology, 2018, 5, e1241854.	0.7	11
46	NSD1: A Lysine Methyltransferase between Developmental Disorders and Cancer. Life, 2021, 11, 877.	2.4	11
47	Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update. Current Opinion in Hematology, 2003, 10, 40-48.	2.5	10
48	Novel insights into the role of aberrantly expressed MNX1 (HLXB9) in infant acute myeloid leukemia. Haematologica, 2019, 104, 1-3.	3.5	10
49	Epigenetic Mechanisms in Acute Myeloid Leukemia. , 2011, 67, 197-219.		8
50	The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models. HemaSphere, 2019, 3, e152.	2.7	8
51	Transforming activities of the NUP98-KMT2A fusion gene associated with myelodysplasia and acute myeloid leukemia. Haematologica, 2020, 105, 1857-1867.	3.5	7
52	Learning from mouse models of MLL fusion gene-driven acute leukemia. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2020, 1863, 194550.	1.9	7
53	Role of the tumor necrosis factor ligand APRIL in Hodgkin's lymphoma: a retrospective study including 107 cases. Experimental Hematology, 2008, 36, 533-534.	0.4	5
54	Insights into molecular pathways for targeted therapeutics in acute leukemia. Swiss Medical Weekly, 2010, 140, w13068.	1.6	5

#	Article	IF	Citations
55	NSD1 in erythroid differentiation and leukemogenesis. Molecular and Cellular Oncology, 2020, 7, 1809919.	0.7	4
56	Leukemic Stem Cells Co-Opt Normal Bone Marrow Niches As a Source of Energy and Antioxidant Defence. Blood, 2017, 130, 94-94.	1.4	3
57	Molecular mechanisms of myeloid malignancies: on the hunt for new therapeutic targets. Drug Discovery Today Disease Mechanisms, 2004, 1, 259-266.	0.8	2
58	The hematopoietic precursor cell in which driver mutations occur is linked to AML aggressiveness â€“ a potential target for personalized medicine. Expert Review of Precision Medicine and Drug Development, 2017, 2, 1-3.	0.7	2
59	Molecular Landscapes and Models of Acute Erythroleukemia. HemaSphere, 2021, 5, e558.	2.7	2
60	Fetal Inactivation of the Nuclear Interacting SET Domain Protein 1 Impairs Terminal Erythroid Maturation and Results in Acute Erythroleukemia in Mice. Blood, 2017, 130, 713-713.	1.4	2
61	MLL-AF4+ infant leukemia: a microRNA affair. Blood, 2021, 138, 2014-2015.	1.4	2
62	Trithorax and polycomb cooperation in MLL fusion acute leukemia. Haematologica, 2013, 98, 825-827.	3.5	1
63	Targeting Aberrant Self-Renewal of Leukemic Cells with a Novel CBP/p300 Bromodomain Inhibitor. Blood, 2014, 124, 3750-3750.	1.4	1
64	Dissecting Proto-Oncogenic PIM Serine/Threonine Kinases in FLT3-ITDInduced Leukemogenesis: PIM1 Regulates CXCL12/CXCR4-Mediated Homing and Migration. Blood, 2008, 112, 3796-3796.	1.4	1
65	Transformation Mechanisms of the Nfia-ETO2 Fusion Gene Associated with Pediatric Pure Acute Erythroleukemia. Blood, 2019, 134, 532-532.	1.4	1
66	Role of Meningioma 1 for maintaining the transformed state in MLL-rearranged acute myeloid leukemia: potential for therapeutic intervention?. Haematologica, 2020, 105, 1174-1176.	3.5	0
67	Writing Constructive Reviews for Scientific Journals. HemaSphere, 2020, 4, e343.	2.7	0
68	PD-1 Signaling on Chronic Myeloid Leukemia-Specific T Cells Results in T Cell Exhaustion and Disease Progression.. Blood, 2007, 110, 2923-2923.	1.4	0
69	Collaboration of the Meningioma 1 (MN1) Oncogene with MLL-Fusions in Pediatric Leukemia. Blood, 2008, 112, 3786-3786.	1.4	0
70	Dissection of PIM serine/threonine kinases in FLT3-ITDâ€“induced leukemogenesis reveals PIM1 as regulator of CXCL12â€“CXCR4-mediated homing and migration. Journal of Cell Biology, 2009, 186, i7-i7.	5.2	0
71	Cellular and Molecular Targets of MLL-AF9 in a Novel Conditional Mouse Model. Blood, 2012, 120, 1280-1280.	1.4	0
72	A Novel Conditional Mouse Model For MLL-ENL Induced Acute Leukemia. Blood, 2013, 122, 1277-1277.	1.4	0

#	Article	IF	Citations
73	Sympathetic Neuropathy Of The Hematopoietic Stem Cell Niche Is Essential For Myeloproliferative Neoplasms. Blood, 2013, 122, 268-268.	1.4	0
74	Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling. Blood, 2014, 124, 2160-2160.	1.4	0
75	Conditional Expression of a Leukemogenic Fusion Oncogene in Murine Hematopoietic Stem Cells Results in Highly Invasive AML with Origin-Related Genetic Signatures of Prognostic Significance for the Human Disease. Blood, 2014, 124, 779-779.	1.4	0
76	Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML. Blood, 2016, 128, 4711-4711.	1.4	0
77	ETO2-GLIS2 Controls Differentiation Arrest and Self-Renewal through Aberrant Enhancers Regulation in Pediatric Leukemia. Blood, 2016, 128, 572-572.	1.4	0
78	Abstract 1892: Discovery of targeted therapies for acute myeloid leukemia patients withNUP98-NSD1andFLT3-ITD. , 2018, , .		0
79	siRNA-mediated inhibition of E2A-PBX1 reduces EB-1 and Wnt16b expression in 697 pre-B leukemia cells. Haematologica, 2006, 91, 724.	3.5	0
80	High-mobility-group protein A1 in MPN progression. Blood, 2022, 139, 2730-2732.	1.4	0